134 related articles for article (PubMed ID: 21109961)
1. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
Zhu H; Pan X; Qi H; Wang X; Hou S; Han B; Liu Z; Xu L
Oncol Rep; 2011 Jan; 25(1):81-90. PubMed ID: 21109961
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma.
Li X; Yang X; Xu Y; Jiang X; Li X; Nan F; Tang H
Cell Res; 2009 Jun; 19(6):720-32. PubMed ID: 19417774
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
Li M; Lee TW; Yim AP; Mok TS; Chen GG
J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
[TBL] [Abstract][Full Text] [Related]
5. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.
Yan KH; Yao CJ; Chang HY; Lai GM; Cheng AL; Chuang SE
Mol Carcinog; 2010 Mar; 49(3):235-46. PubMed ID: 19908241
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
7. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand.
Nonaka M; Tazuma S; Hyogo H; Kanno K; Chayama K
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e198-206. PubMed ID: 17868335
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
10. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma.
Fujita M; Yagami T; Fujio M; Tohji C; Takase K; Yamamoto Y; Sawada K; Yamamori M; Okamura N
Cancer Lett; 2011 Dec; 312(2):219-27. PubMed ID: 21903322
[TBL] [Abstract][Full Text] [Related]
12. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
14. EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.
Chbicheb S; Yao X; Rodeau JL; Salamone S; Boisbrun M; Thiel G; Spohn D; Grillier-Vuissoz I; Chapleur Y; Flament S; Mazerbourg S
Biochem Pharmacol; 2011 May; 81(9):1087-97. PubMed ID: 21338579
[TBL] [Abstract][Full Text] [Related]
15. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
16. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma.
Chaffer CL; Thomas DM; Thompson EW; Williams ED
BMC Cancer; 2006 Mar; 6():53. PubMed ID: 16519808
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin.
Kim JH; Xu C; Keum YS; Reddy B; Conney A; Kong AN
Carcinogenesis; 2006 Mar; 27(3):475-82. PubMed ID: 16299382
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
19. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
[TBL] [Abstract][Full Text] [Related]
20. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
Chen A; Xu J
Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G447-56. PubMed ID: 15486348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
